Regeneron Pharmaceuticals, Inc.
Explore Regeneron Pharmaceuticals
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
3 leaders · Full leadership timeline
Regeneron sits in biotechnology, where scientific productivity, regulatory execution, reimbursement, and patent life determine long-term economics.
Regeneron makes money from direct product sales and collaboration revenue. U.S. EYLEA and EYLEA HD sales, global Libtayo sales, rare-disease medicines, Sanofi profit-share economics for Dupixent, and Bayer EYLEA collaboration revenue are the main pillars.
Co-Founder, President, and CEO
Built Regeneron as a founder-led biotechnology company and oversaw its transition from platform research to scaled commercial medicines.
Co-Founder, President, and Chief Scientific Officer
Led the science organization behind VelociSuite technologies and many internally discovered programs.
Executive Vice President and Head of Commercial
Leads commercial execution across major products and launch priorities.
Regeneron's biggest challenges are EYLEA biosimilar and branded competition, product concentration, payer pricing pressure, high R&D spend, clinical trial risk, and the difficulty of turning newer modalities into approved medicines.
Leonard S. Schleifer, M.D., Ph.D. is Regeneron's president and CEO.
Schleifer has led Regeneron since founding the company in 1988.
The leadership priority is defending EYLEA, scaling Dupixent economics, and turning pipeline science into new approved medicines.
Leonard Schleifer and George Yancopoulos are the defining leaders in Regeneron's history.